> Detailanzeige

McNerney, Kevin O.; Si Lim, Stephanie J.; Ishikawa, Kyle; Dreyzin, Alexandra; Vatsayan, Anant; Chen, John J.; Baggott, Christina; Prabhu, Snehit; Pacenta, Holly L.; Philips, Christine; Rossoff, Jenna; Stefanski, Heather E.; Talano, Julie-An; Moskop, Amy; Verneris, Michael; Myers, Doug; Karras, Nicole A.; Brown, Patrick; Bonifant, Challice L.; Qayed, Muna; Hermiston, Michelle; Satwani, Prakash; Krupski, Christa; Keating, Amy K.; [...]

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL
  • Beteiligte: McNerney, Kevin O.; Si Lim, Stephanie J.; Ishikawa, Kyle; Dreyzin, Alexandra; Vatsayan, Anant; Chen, John J.; Baggott, Christina; Prabhu, Snehit; Pacenta, Holly L.; Philips, Christine; Rossoff, Jenna; Stefanski, Heather E.; Talano, Julie-An; Moskop, Amy; Verneris, Michael; Myers, Doug; Karras, Nicole A.; Brown, Patrick; Bonifant, Challice L.; Qayed, Muna; Hermiston, Michelle; Satwani, Prakash; Krupski, Christa; Keating, Amy K.; [...]
  • Erschienen: American Society of Hematology, 2023
  • Erschienen in: Blood Advances
  • Sprache: Englisch
  • DOI: 10.1182/bloodadvances.2022008893
  • ISSN: 2473-9529; 2473-9537
  • Schlagwörter: Hematology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:p>Chimeric antigen receptor–associated hemophagocytic lymphohistiocytosis (HLH)–like toxicities (LTs) involving hyperferritinemia, multiorgan dysfunction, coagulopathy, and/or hemophagocytosis are described as occurring in a subset of patients with cytokine release syndrome (CRS). Case series report poor outcomes for those with B-cell acute lymphoblastic leukemia (B-ALL) who develop HLH-LTs, although larger outcomes analyses of children and young adults (CAYAs) with B-ALL who develop these toxicities after the administration of commercially available tisagenlecleucel are not described. Using a multi-institutional database of 185 CAYAs with B-ALL, we conducted a retrospective cohort study including groups that developed HLH-LTs, high-grade (HG) CRS without HLH-LTs, or no to low-grade (NLG) CRS without HLH-LTs. Primary objectives included characterizing the incidence, outcomes, and preinfusion factors associated with HLH-LTs. Among 185 CAYAs infused with tisagenlecleucel, 26 (14.1%) met the criteria for HLH-LTs. One-year overall survival and relapse-free survival were 25.7% and 4.7%, respectively, in those with HLH-LTs compared with 80.1% and 57.6%, respectively, in those without. In multivariable analysis for death, meeting criteria for HLH-LTs carried a hazard ratio of 4.61 (95% confidence interval, 2.41-8.83), controlling for disease burden, age, and sex. Patients who developed HLH-LTs had higher pretisagenlecleucel disease burden, ferritin, and C-reactive protein levels and lower platelet and absolute neutrophil counts than patients with HG- or NLG-CRS without HLH-LTs. Overall, CAYAs with B-ALL who developed HLH-LTs after tisagenlecleucel experienced high rates of relapse and nonrelapse mortality, indicating the urgent need for further investigations into prevention and optimal management of patients who develop HLH-LTs after tisagenlecleucel.</jats:p>
  • Zugangsstatus: Freier Zugang